InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today ann...
Lilly, MiNA ink agreement to upregulate proteins using RNA Eli Lilly will utilise the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus. Eli Lilly declared a drug development ...
Find More
Abingworth Achieves Financial Close, Raises USD 582 Million Abingworth, a London-based venture capital firm, has announced the closing of its new Clinical Co-Development Fund 2 (ACCD 2) worth USD 582 million, however, the fund was aiming to gather USD $350 million. Not long ago, the company also closed ...
Find More
Pfizer suffers a DMD delay and halts BCMA trials amid safety woes Pfizer has paused after seeing three cases of peripheral neuropathy in an early-stage study, enrollment in a critical analysis of its anti-BCMA bispecific antibody. Big Pharma shares news with details of delays to the start of the US part of...
Find More
Zimmer Biomet Receives FDA Approval for its Rosa System On 20 April 2021, Zimmer Biomet received FDA 510(k) clearance for its Rosa Partial Knee system for robotically-assisted partial knee replacement surgeries. This is the new edition to Zimmer Biomet's Rosa Robotics platform, which comprises the Rosa Knee syst...
Find More
Arch Oncology scores USD 105 Million for anti-CD47 med in solid tumors, multiple myeloma Arch Oncology scored USD 105 million from new and old backers to expand the drug’s journey through the clinic and into new trials, having moved its anti-CD47 antibody into a phase 1/2 study. Arch tests the drug alon...
Find More
Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies compete against bluebird bio to the market with a novel gene-editing therapy for sickle cell disease and beta-thalassemia called CTX001. B...
Find More
Adagio Raises $336 Million to Advance Covid-19 Antibody Treatment An antibody startup Adagio Therapeutics announced the completion of a $336 million Series C financing round. The proceedings from the financing round will be used to augment the development of the company’s lead program developing treatments for C...
Find More
Lilly’s RET inhibitor Retevmo exhibits early promise in new cancer types The phase 1/2 LIBRETTO-001 trial enrolled 32 patients with 12 unique RET fusion-positive advanced cancer types, comprising pancreatic, colon, breast and salivary cancer, with 62.5% affected by gastrointestinal tumours. Across all 32 pati...
Find More
Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading patient advocacy group for an upfront payment of USD 5.5 million. TSHA-120 is an intrathecally dosed AAV9 gene therapy designed to tre...
Find More
Over the years, the Oncology domain has experienced the entry of several treatment approaches. Thera.....
Find More
Multiple myeloma (MM) is a cancer of the blood that begins in the bone marrow. In myeloma, plasma ce.....
Find More
IPSCs have enormous applications in the field of regenerative medicine, disease modelling, and drug .....
Find More
Nestlé and Unilever are multinational corporations established in 1866 and 1930, respectively. The .....
Find More
The gene therapy in rare diseases market has drastically changed recently due to scientific advancem.....
Find More
Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
